NU-6027

CAS No. 220036-08-8

NU-6027 ( NU6027;NU 6027 )

Catalog No. M13509 CAS No. 220036-08-8

NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 34 Get Quote
5MG 55 Get Quote
10MG 91 Get Quote
25MG 186 Get Quote
50MG 295 Get Quote
100MG 441 Get Quote
500MG 981 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NU-6027
  • Note
    Research use only, not for human use.
  • Brief Description
    NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.
  • Description
    NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively; inhibits human tumor cells with a mean GI50 of 10 ±6 uM; also inhibits cellular ATR (IC50=6.7 uM) and RAD51 focus formation, increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy.
  • Synonyms
    NU6027;NU 6027
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ATR;CDK1;CDK2;DNA-PK
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    220036-08-8
  • Formula Weight
    251.30
  • Molecular Formula
    C11H17N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 47 mg/mL (187 mM); Ethanol: 3 mg/mL (11.93 mM); Water: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    NC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1
  • Chemical Name
    6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arris CE, et al. J Med Chem. 2000 Jul 27;43(15):2797-804.
2. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81.
3. Boschi D, et al. Eur J Med Chem. 2013 Oct;68:333-8.
molnova catalog
related products
  • HQ461

    HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.

  • BML-259

    BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.

  • Palbociclib hydrochl...

    A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.